Moneycontrol PRO

HomeNewsBusinessMoneycontrol ResearchIPCA Labs guidance should move investor focus beyond HCQS, accumulate

IPCA Labs guidance should move investor focus beyond HCQS, accumulate

There is much more to IPCA Labs than the HCQS opportunity. Its FY21 guidance reflects that.

Anubhav Sahu

July 06, 2020 / 17:32 IST

IPCA Labs guidance should move investor focus beyond HCQS, accumulate

Bharat Immunologicals & Biologicals Corporation | In the last four months, the stock price has risen 444 percent to Rs 31.34 per share from Rs 5.76 per share on March 27, 2020.

Watch Webinar

PRO Panorama

Moneycontrol Pro Panorama | IPO Paradox: Fundraising soars, returns shrink

Nov 27, 2025 / 03:36 PM IST

Moneycontrol Pro Panorama November 27 edition: IMF advises India to keep policy flexible until clarity on US tariff, the banking l...
Read Now
PRO Weekender

Moneycontrol Pro Weekender | Samvat 2082: The Will to Rise

Oct 18, 2025 / 10:00 AM IST

After a turbulent Samvat 2081, the markets step into the new year not with fireworks but with quiet resolve and the will to rise
Read Now

Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More